Inflammation

Bimekizumab Well Tolerated, Efficacious Over Three Years in Axial Spondyloarthritis

Physician’s Briefing

Bimekizumab Well Tolerated, Efficacious Over Three Years in Axial Spondyloarthritis

09 Jul 2026

2 min read

EULAR: Obexelimab Can Lower Risk for Disease Flare in Active IgG4-Related Disease

Physician’s Briefing

EULAR: Obexelimab Can Lower Risk for Disease Flare in Active IgG4-Related Disease

08 Jun 2026

2 min read

ESC: Mortality Increased for Patients With Heart Failure and Low BMI, High Waist-to-Hip Ratio

Physician’s Briefing

ESC: Mortality Increased for Patients With Heart Failure and Low BMI, High Waist-to-Hip Ratio

20 May 2026

2 min read

Read More

Clinical Briefing Report

clinicalbriefingreport.com